HEALTHCARE SPENDING News & Analysis

We assume that pharmaceutical tariffs will be enacted. While this could bring short-term margin pressure, we have not changed our valuations.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

These wide-moat, low-uncertainty names are reliable, writes Susan Dziubinski.

These common trouble spots can catch retirees off guard (who don't plan for them).

And Morningstar analysts say Australian names such as CSL and ResMed are set to benefit, writes Nicki Bourlioufas.

The Democrat's platform proposes major new spending programs, including healthcare, clean/renewable energy, infrastructure, and education, among...

Local names are tipped to rebound as the pandemic forces a contraction in Australia’s economy.

China’s new economy sectors are forecast to rebound from the short-term sell-off and continue to do relatively well.

An examination of the perilous state of the economy topped our coverage this week, alongside a look at opportunities in healthcare and Morningstar's...

The Coalition's budget is a blatant election pitch, trumpeting a return to surplus and rich in tax cuts, concessions for small business and...